run oncology to great value To battling need survival is our all accomplish we There on successful and business It's and cancer. are commercializing to quality for of Brian. to Thanks, to goal, we that dedicated improve patients some medicines you that and developing generate of life have board. of the a need stakeholders.
fulfill end, plan new integrated our company To articulating today allow we're and vision both short achieve corporate will of sustainable we believe and fully growth. a that biopharma us a long-term to that
the we'll following be towards key forward, working corporate objectives. Going
have and months is goal revenues commercial positive to trajectory time, spend. six a in our upward closing First, between at COPIKTRA aimed on gap revenue the
assets in along the our in to Next, to COPIKTRA achieve development. the goal flow for marketed our COPIKTRA years five product with program. time, And at is both broaden least even is cash one and of indications in have break for finally, years commercial robust time, goal pipeline two a additional and clinical
executive strong team and now place five with and have his and team the plan we a other to place this marketing expertise, And deep these in Oncology, in capabilities indications. COPIKTRA achieve the into six leading Brian leadership high commercial believe advancing need right to duvelisib we contributing Verastem goals. unmet in
supportive our data external clinical along the with now development ongoing the internal front, programs. to collaborators at the clinical very team been development gears duvelisib Shifting and year expansion active presenting development this generating have to
In led ASCO. at and by a Dr. presented study Flinn Ian
of of days rates dosing resulted to New and in demonstrated shown similar free on dose the median the XX.X label. data dose data XX COPIKTRA a – new progression modification month survival that interruptions response
more on cancer disease hear keeping alternative alternative Going to and that of forward, recognize a being studies clinical we our is longer complicated achieving regimens. development that better clinical may and are conducted patients believe dosing strategy. you'll regimens hold investigate about We outcomes. to drug the part key dosing studies begin are potentially These broader that to
a in lymphocytes rapidly a with resulted EHA achieving of the poster, node to in nodes were up similar lymphocytosis also XX% resolution with Dr. Notably, weeks. which of patients. COPIKTRA patients Barrientos lymph highlighted resulted lymph response. increased Jacqueline At of data presented COPIKTRA in XXXX at risk and shrinkage the treatment high XX
rates. ICML presentation highlighting PTCL, patients finally meeting ongoing gave XXXX with response Steven data lymphoma refractory And the preliminary, demonstrated the studies evaluating clinical at or activity and peripheral aggressive trend T-cell Phase form from clinical Phase considered in in relapsed PTCL patients in oral studies. studies of of positive reasonable of an investigator duvelisib with preliminary an lymphoma. treated or patients non-Hodgkin's X PRIMO duvelisib including two lead both was Across prior refractory compelling safety profile or X company's a duvelisib but with The consistent supportive with Dr. study Horwitz relapsed
efficacy The goal clinical duvelisib company monotherapy the PTCL. multi-center regimen efficacy safety refractory and is of refractory the Phase to X with PRIMO characterize PRIMO relapsed sponsored guidance PTCL, and relapsed in its open-label on to evaluating patients population. study duvelisib patients monotherapy ongoing Phase trial of an in tolerability this a X to with provide to dosing study and is The further in
PRIMO commenced was from the study dose dose to expected optimization enroll expect the patients data completed total approximately this later the study. the dose expansion year. recently phase in We optimization initial and have the report to phase we phase XXX of of and
I/II an relapsed of inhibitor CLL/SLL. an selective study venetoclax, ongoing of combination Another oral duvelisib patients Phase trial is BCLX in investigator-sponsored or with refractory in note evaluating with
trial dose the for I primary recommended venetoclax Phase portion regimen. and the determine of The maximum Phase combination are to tolerated the II dose this this of of objectives
Dr. mentioned initiate settings. quarter, evaluating is of saw evaluating ISTs Hematologist clinical and being the Health intermittent who physicians numerous such As significant Medicine during & a second duvelisib dosing receiving relapsed of the We Oregon with Alexey CLL/SLL. seeking a in leading Portland, we've Oregon. being at Phase earlier, study, and conducted been lymphoma in by University specializes in duvelisib study II to interest This investigator-sponsored the two Danilov, including refractory from in initiation is School of Science I patients studies led CLL
Richter Syndrome study Cancer Phase Jennifer Dr. for I Woyach dosing safety of duvelisib State is Ohio or regimens This being transformed University patients study treatment conducted a evaluating Comprehensive with and with by in being led combination Center. FL. nivolumab and for at is the also And
control we'll providing items data on all related timing As a these their physicians the any so trials guidance aspects behalf. on including reminder, of not be
trials. these In working company trials, addition of sponsored towards key ongoing two also we're initiation to
response tumor will a of patients prior which on dosing we'll systemic a have named Phase or Tempo lymphoma and one the One indolent two-week therapy. with in evaluating received non-Hodgkin's study be [ph] safety effect is refractory least randomized relapsed label and dosing II who planned intermittent open be holiday at
will multi-center approval to study expected XXXX. We've XXX received and IRB approximately enroll patients during the this commence third is quarter for of which
for in this year. FL aimed the we're phase look final on Phase to Additionally, the FDA into a with details We're in III forward COPIKTRA commencing accelerated working at this and the preparation converting of final approval. we later trial approval confirmatory full study
I'd to the the over that, for call financials. With like to turn Rob
